Skip to main content
Premium Trial:

Request an Annual Quote

Biofortuna to Use TriLink dNTPs in Diagnostic PCR Kits

Premium

TriLink BioTechnologies said this week that it has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna's freeze-dried in vitro diagnostic PCR kits.

Biofortuna will use the dNTPs for a line of human leukocyte antigen diagnostic kits it is developing for the transplantation, blood grouping, disease identification, and pharmacogenetic markets. The company is targeting its first product for the sequence-specific primer transplantation market.

TriLink said that Biofortuna was able to improve the specificity of its genotyping assays by replacing standard dNTPs with CleanAmp dNTPs.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.